BCYC Bicycle Therapeutics
- 20.260
- -0.100-0.49%
- 20.260
- 0.0000.00%
Bicycle Therapeutics News
Bicycle Therapeutics Initiated at Equal-Weight by Stephens & Co.
Bicycle Therapeutics Analyst Ratings
Stephens Initiates Bicycle Therapeutics(BCYC.US) With Hold Rating, Announces Target Price $25
Morgan Stanley Initiates Bicycle Therapeutics(BCYC.US) With Hold Rating, Announces Target Price $30
JMP Securities Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $32
Barclays Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $40
H.C. Wainwright Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $55
RBC Capital Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $35
RBC Capital Reiterates Outperform on Bicycle Therapeutics, Maintains $35 Price Target
A Quick Look at Today's Ratings for Bicycle Therapeutics(BCYC.US), With a Forecast Between $32 to $55
Bicycle Therapeutics Analyst Ratings
Leerink Partners Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Announces Target Price $30
A Quick Look at Today's Ratings for Bicycle Therapeutics(BCYC.US), With a Forecast Between $32 to $55
Navigating 11 Analyst Ratings For Bicycle Therapeutics
Optimistic Buy Rating for Bicycle Therapeutics Amid Promising Imaging Data and Strategic Market Positioning
Oppenheimer Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $48
Oppenheimer Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $48
Oppenheimer Keeps Their Buy Rating on Bicycle Therapeutics (BCYC)
Jefferies Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $56
Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC) and Radnet (RDNT)
Analysis
Price Target
No Data
No Data